Hänggi, Daniel
Etminan, Nima
Mayer, Stephan A.
Aldrich, E. Francois
Diringer, Michael N.
Schmutzhard, Erich
Faleck, Herbert J.
Ng, David
Saville, Benjamin R.
Macdonald, R. Loch
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)]
https://doi.org/10.1007/s12028-018-0575-z
Funding for this research was provided by:
Edge Therapeutics, Inc.
Article History
First Online: 16 July 2018
Compliance with Ethical Standards
:
: RL. Macdonald receives grant support from the Brain Aneurysm Foundation and the Canadian Institutes for Health Research and is Chief Scientific Officer of Edge Therapeutics, Inc. D. Hänggi, N. Etminan, F. Aldrich, S.A. Mayer, M.N. Diringer, and E. Schmutzhard receive consulting fees from Edge Therapeutics, Inc. for serving on the steering committee for this study and for advising Edge Therapeutics, Inc. H.J. Faleck is an employee of Edge Therapeutics, Inc. D. Ng is an employee of ResearchPoint Global. B.R. Saville is an employee of Berry Consultants.